* China sales, cancer drug sales soar
* Tagrisso sales nearly double
* Sees FY product sales growth in low double-digit percentage
* Shares surge over 8% to hit record high (Adds analyst comment, background; updates shares)
By Pushkala Aripaka and Ankur Banerjee
July 25 (Reuters) - AstraZeneca Plc raised its product sales forecast for 2019 on Thursday after second-quarter results beat analysts’ expectations, thanks to strong sales from cancer medicines and emerging markets, especially China.
The British drugmaker’s shares rose more than 8% to hit a record high of 6,581 pence by 1423 GMT, bringing gains for the year so far to nearly 17% as Chief Executive Officer Pascal Soriot’s turnaround plan gained traction.
AstraZeneca, which maintained its dividend, reported a rise in drug sales for the fourth consecutive quarter after posting years of decline in sales due to patent losses on older drugs.
“The momentum generated last year continued into the first half, consolidating AstraZeneca’s return to growth based on the strength of our new medicines,” Soriot said. “We are very optimistic for the next few quarters.”
Sales from its oncology unit soared 57% to $2.17 billion, accounting for 38% of total product sales, with revenue from the company’s top-seller - lung cancer drug Tagrisso - nearly doubling to $784 million.
“We appear to be in the middle of a positive run for the near term. This is likely to be the case for the short to medium term,” David Madden, a market analyst at CMC Markets told Reuters, but added the market would be looking at what was next in the pipeline.
“You can’t be dining out on the success of one cancer drug forever.”
The company has moved deeper into cancer therapy through wide-ranging deals, including those for immunotherapy and targeted therapy. Earlier this year, it agreed a multi-billion dollar oncology deal with Japan’s Daiichi Sankyo Co.
AstraZeneca’s focus on China has also resulted in explosive growth, with sales more than doubling since 2012 on the back of partnerships with local players and a softening of the regulatory environment for pharmaceutical firms.
Chinese sales rose 44% in the three-month period to $1.17 billion, accounting for more than half of its sales in the developing world.
(For an interactive graphic on AstraZeneca's oncology and China growth, click here tmsnrt.rs/2y80M5t)
The drugmaker, however, has warned that growth may not be sustainable.
“We are very pleased with overall performance of China,” Ruud Dobber, executive vice president, BioPharma, told Reuters, but added the company still expected changing policies in the country to hurt sales of its cholesterol drug, Crestor.
China has been a bright spot for other companies, including Swiss drugmaker Roche and Dutch health technology company Philips, which posted better-than-expected quarterly sales growth earlier this week due to rising healthcare spending by the Chinese government.
AstraZeneca said it now expects full-year product sales to increase by a low double-digit percentage, compared to a previous forecast of high single-digit percentage growth but it maintained its forecast for 2019 core earnings.
Quarterly sales rose 19% to $5.72 billion at constant currency, above analysts’ consensus of $5.45 billion.
Core earnings were 73 cents per share, beating analysts’ average expectation of 61 cents per share, according to a company provided consensus.
Like other players, AstraZeneca has been one of the focal points for concern over supplies of drugs if Britain leaves the European Union without a withdrawal deal later this year.
The company reiterated on Thursday that it was prepared for the breakup, even if it was a no-deal exit.
“We are as ready as we can be,” Soriot added.
Reporting by Pushkala Aripaka and Ankur Banerjee in Bengaluru; Editing by Patrick Graham and David Evans